<DOC>
	<DOC>NCT00806923</DOC>
	<brief_summary>This 3 arm study will evaluate the efficacy and safety of adding Avastin versus placebo to a standard chemotherapeutic regimen in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) who have not received prior chemotherapy. The anticipated time of study treatment is until disease progression, and the target sample size is 500+ individuals.</brief_summary>
	<brief_title>A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>adult patients, &gt;=18 years of age; documented inoperable, locally advanced, metastatic or recurrent nonsquamous NSCLC; adequate liver and kidney function; women of childbearing potential must have a negative serum pregnancy test within 7 days of starting study treatment. prior chemotherapy or treatment with another systemic cancer therapy; surgery (including open biopsy), significant traumatic injury, or radiotherapy within the last 4 weeks prior to first dose of study treatment; brain metastasis or spinal cord compression; fertile men, and women of childbearing potential, not using adequate contraception; treatment with any other investigational agent, or participation in another clinical trial, within 30 days prior to entering the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>